| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10802541 | Biochimica et Biophysica Acta (BBA) - Molecular Cell Research | 2012 | 11 Pages |
Abstract
âºInhibitors of HSP90 have been valuable probes in learning how this chaperone supports malignancy. âºClinical activity for first generation inhibitors has been limited against advanced cancers. âºNext generation drugs with better pharmacology are more promising, but remain far from curative. âºCombining HSP90 inhibitors with other anticancer drugs could limit the evolvability of cancers. âºHurdles arise in executing trials that combine proprietary agents, but the rewards could be great.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Luke Whitesell, Nancy U. Lin,